Huapu Science and Technology Secures RMB 100 Million in Angel Funding to Propel Domestic Chromatography Innovation

VCBeat (WeChat ID: vcbeat) has learned that recently, Acchrom Tech (Beijing) Co., Ltd. (hereinafter referred to as “Acchrom Tech”) announcedCompleted 100 Million Yuan Angel Round Financing, led by BioTrack Capital, with follow-on investments from Chende Capital and SDIC Chuanghe. The funds raised in this round will be primarily used for the company'sFurther Enhance the Capability to Provide Comprehensive Chromatography Solutions for Customers, as well as the expansion of sales channels. Changhai Capital served as the exclusive financial advisor for this round of financing.

Chromatography represents the largest single-product market in the field of life sciences analysis. It is widely used in pharmaceuticals, chemicals, environmental monitoring, and clinical testing, primarily serving a metrological role. Currently, China’s installed base market exceeds RMB 10 billion annually and continues to grow. However, the liquid chromatography market in China is currently dominated by a few major foreign manufacturers, with domestic brands accounting for less than 5% of the market share. This situation stems from two main factors: on one hand, there is a gap between domestic and imported brands in terms of hard capabilities such as instrument and consumable performance; on the other hand, domestic manufacturers lack specialized application service teams tailored to specific implementation scenarios, failing to provide customers with ready-to-deploy solutions. Customers often require ad hoc manufacturer intervention during use, which further deepens their distrust of domestic brands.

Acchrom Tech, founded in 2015, is one of the few high-end Chinese chromatography brands capable of breaking the monopoly held by foreign brands and achieving a fully closed-loop integration of chromatography equipment, consumables, software, and services.Wang Lichun, the company’s founder and chairman, has over 10 years of sales and management experience in the chromatography and mass spectrometry industry, with a profound understanding of the underlying technologies of chromatography and the industry’s pain points. On the technical front, the company has assembled a team from China’s leading chromatography research institutions.Dalian Institute of Chemical Physics, and a team of senior R&D professionals and engineers from multiple well-known scientific instrument companies, to build a comprehensive product portfolio; the sales team consists ofMr. Yu Xiaoran, Former General Manager of Waters ChinaLed by a team of senior industry experts, it boasts extensive client channels and, tailored to the characteristics of Chinese clients, offers more practical and implementable application services.

Currently, Acchrom Tech has established a comprehensive product portfolio of HPLC (High-Performance Liquid Chromatography) and UHPLC (Ultra-High-Performance Liquid Chromatography) systems, featuring a full range of detectors to meet diverse customer detection needs.The installed base of our proprietary-brand instruments in the mainstream chromatography application market has reached the thousands, with extensive coverage across major pharmaceutical companies, food enterprises, research institutes, and government agencies.. The product's performance metrics, including accuracy, stability, and injection precision, are benchmarked against those of leading international manufacturers, earning deep recognition from customers.

The Company adopts a diversified sales strategy and collaborates with multiple national, provincial, and municipal regulatory authorities to jointly formulate and update national standards, thereby promoting the “China Product Solution.”Currently, Acchrom Tech’s instruments have been deployed in national-level and multiple first-tier provincial drug testing institutes and centers for disease control and prevention., garnering widespread attention from expert leaders. In February this year, the company alsoStrategic Partnership with International Mass Spectrometry Brand SCIEX, jointly developing domestically produced liquid chromatography-mass spectrometry (LC-MS) systems to help the company build a more complete product ecosystem for its chromatography portfolio.

SCIEX (Left) and Acchrom Tech (Right) Sign Strategic Cooperation Agreement

Acchrom Tech has established a comprehensive system for chromatography columns (consumables), software, and application services through years of development, forming a complete product ecosystem together with its instruments. The companyA Series of Chromatography Columns Developed for Different Applications, Including Pharmaceutical and Life Science Analysis, demonstrating excellent performance in terms of resolution, stability, and other key attributes;Web-Based Compliance Software, having secured the key to unlocking core B-end markets such as pharmaceutical enterprises; it has accumulated a vast portfolio of SOP solutions across sectors including food, chemical drugs, traditional Chinese medicine (TCM), innovative drugs, and environmental protection, while its high-quality, cost-effective application services have significantly enhanced user stickiness.

In recent years, as the international landscape has shifted, China has placed increasing emphasis on overcoming critical technological bottlenecks. The momentum for domestic substitution, initially seen in clinical devices and pharmaceuticals, is gradually extending upstream to more advanced and sophisticated life science tools—a trend profoundly felt within the chromatography industry. As a veteran of the sector, Wang Lichun shares his deep reflections: “In the past, Chinese chromatography products suffered from two main issues: subpar quality and the fact that standards were set by foreign manufacturers, leaving little opportunity for domestic products to enter the market even if they wished to compete. Since 2019, a series of national policies—including the implementation of new national standards, incentives in local procurement tenders, and support from experts and academics—have significantly enhanced opportunities for domestic products in the market. Many of us entrepreneurial partners previously worked at major multinational corporations. We feel a strong responsibility to seize this opportunity and contribute to China’s goal of achieving self-reliance in life science tools.”

To this end, Acchrom Tech is systematically advancing its strategic layout across R&D, marketing, and sales. Looking ahead, in addition to its presence in the liquid chromatography and mass spectrometry sectors, Acchrom Tech will continue to expand and innovate in ion chromatography, other high-end laboratory instruments, and consumables, striving to become a platform enterprise for life science tools in China.

Acchrom Tech’s S6000 Self-Developed Instrument and Chromloong’s Proprietary Chromatography Software Deployed at a Provincial Institute for Drug Control

Li Han, Vice President of BioTrack Capital, stated: Scientific instruments are not only tools for exploring the unknown world but also the foundation of technological innovation. The domestic scientific instrument industry in China started late and has a weak foundation, with various high-end scientific instruments, represented by chromatography and mass spectrometry systems, long relying on imports. In recent years, from the national and local governments to end-users, there has been greater emphasis on and support for domestically produced scientific instruments, and the opportunity for the rise of this industry is brewing. BioTrack Capital has long focused on the field of scientific instruments and has already invested in several companies, including HanChen GuangYi (fully automated high-throughput genetic testing systems), XunYin Biology (single-cell sequencing systems), QiTan Technology (nanopore sequencing systems), and YuCe Biology (single-molecule immune systems). Chromatography and mass spectrometry are the largest categories of analytical instruments. The founding team of Acchrom Tech has been deeply rooted in this field for many years, accumulating multiple self-developed technologies and forming a complete closed loop encompassing instruments, consumables, software, applications, and after-sales services. We highly recognize the team’s resilience and determination as well as their profound industry expertise, and we believe that Acchrom Tech will become a leading enterprise in China’s scientific instrument sector in the future.

Chende Capital stated:The field of life science instruments is one of the key focus areas for Chende Capital.Acchrom Tech’s team has previously established successful liquid chromatography analysis applications across multiple industries.Meanwhile, through independent R&D and strategic collaborations, the company has amassed substantial expertise in hardware, software, systems, and consumables. During our engagements with Acchrom Tech, we have been deeply impressed by Founder Mr. Wang and his team’s profound industry insights, enterprising entrepreneurial spirit, and pragmatic approach. Under the leadership of Mr. Wang and his professional team, we hope that Acchrom Tech will continue to deliver exceptional products and services with a strong reputation, swiftly establishing itself as a benchmark enterprise in the chromatography analysis industry.

The SDIC Chuanghe Biopharmaceutical Team stated:Acchrom Tech’s team possesses profound expertise in liquid chromatography separation technology and has established a comprehensive ecosystem of chromatography products alongside a professional service system. SDIC Chuanghe will support Acchrom Tech in refining its leading product portfolio in life science instruments, increasing R&D investment, further strengthening its technological and service capabilities, and realizing its brand vision.

Wang Keshu, Partner at Changhai Capital, stated:It is a great honor to assist Acchrom Tech in completing its first round of financing, laying a solid foundation for the company’s rapid future growth. With increasing national emphasis on this sector, the localization of high-end life science instruments is entering a breakthrough era. We believe that Acchrom Tech’s comprehensive product ecosystem, robust talent pool, and strong market channel expansion capabilities will collectively propel it to become an industry leader, spearheading a new wave of domestic substitution for core R&D and production equipment across pharmaceuticals, chemicals, environmental protection, and other fields.

BioTrack Capital, established in 2017, is a professional investment firm dedicated to investing in and incubating outstanding healthcare startups in the Chinese market. Currently, BioTrack Capital manages two RMB funds and two USD funds, with total assets under management exceeding RMB 7 billion. More than just an investor, BioTrack Capital serves as a long-term partner to entrepreneurs. Since its inception, the firm has remained entrepreneur-centric, consistently supporting and actively empowering exceptional founders in the healthcare sector, fostering an industry ecosystem, and cultivating the next generation of leading enterprises in China’s healthcare industry.

Chende Capital is an investment institution focused on innovative medical technologies and frontier biotechnology sectors, managed and operated by a professional team with extensive backgrounds in the healthcare industry. It manages multiple RMB and USD funds.

Chende Capital adheres to the investment philosophy of “focus, excellence, and reputation.” Leveraging its deep industrial resources in the healthcare sector and years of in-depth research and cultivation, the firm promptly identifies the latest international technological trends and seizes investment opportunities driven by technological innovation. Committed to discovering top-tier companies with industry leadership potential, Chende Capital employs an interconnected, win-win investment methodology and a precise, pragmatic post-investment empowerment system. By co-building an industrial ecosystem and growing alongside entrepreneurs, the firm delivers sustainable, superior returns to its investors.

SDIC Chuanghe is the professional fund-of-funds and industrial fund management arm of SDIC (State Development & Investment Corp.), with directly managed assets exceeding RMB 40 billion. It focuses on equity investment, venture capital, and fund investments in strategic emerging industries. Under the advocacy of the National Development and Reform Commission, it spearheaded the establishment of China’s Venture Capital Service Alliance for Innovative Biomedicine, Artificial Intelligence, New Materials, and Cybersecurity. As a council member of the Asset Management Association of China, SDIC Chuanghe continuously refines its investment ecosystem, pools the collective strength of mass entrepreneurship and innovation, and drives the development of emerging industries.

Changhai Capital is a financial advisory firm specializing in the healthcare sector, providing companies with in-depth, customized financing strategies and services. The team possesses extensive industry experience across life sciences, medical devices, in vitro diagnostics (IVD), and healthcare services. It has led or participated in the financing rounds of numerous high-profile enterprises, helping them achieve rapid growth and maximize their value.